BioAtla (NASDAQ:BCAB) Trading Down 4.6% – What’s Next?

BioAtla, Inc. (NASDAQ:BCAB) dropped 4.6% during mid-day trading on Friday . The stock traded as low as $3.30 and last traded at $3.33. Approximately 113,187 shares changed hands during mid-day trading, an increase of 156% from the average daily volume of 44,150 shares. The stock had previously closed at $3.49.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded BioAtla to a “hold” rating in a report on Saturday, April 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $200.00.

BioAtla Stock Down 4.6%

The firm has a fifty day simple moving average of $4.75 and a 200-day simple moving average of $16.43. The company has a market cap of $5.53 million, a PE ratio of -0.08 and a beta of 0.79.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Friday, May 15th. The company reported ($4.22) EPS for the quarter, topping the consensus estimate of ($10.00) by $5.78.

Hedge Funds Weigh In On BioAtla

Several institutional investors have recently bought and sold shares of BCAB. Acadian Asset Management LLC raised its holdings in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of BioAtla during the 4th quarter worth approximately $508,000. Millennium Management LLC grew its holdings in BioAtla by 123.4% in the fourth quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock valued at $433,000 after purchasing an additional 421,072 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of BioAtla during the 4th quarter worth $104,000. Finally, Susquehanna International Group LLP grew its stake in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares during the last quarter. 77.23% of the stock is owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.